Medscape published a report on research by Ambria Moten, MD, MS, Surgery Resident at Temple University Hospital, and colleagues, that found that about a quarter of all patients with low-risk thyroid cancer are still receiving radioactive iodine (RAI) therapy despite recommendations against its use in the patient population. The research was published in the June issue of Surgical Oncology.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH